Postoperative development of aspirin resistance following coronary artery bypass

European Journal of Clinical Investigation

Volumn 39, Issue 9, 2009, Pages 769-774

  Kempfert, J ^a,b   Anger, K ^a   Rastan, A ^a   Krabbes, S ^a   Lehmann, S ^a   Garbade, J ^a   Sauer, M ^a   Walther, T ^a   Dhein, S ^a   Mohr, F W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

Author keywords

Aspirin; CABG; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COUMARIN; HEPARIN;

ARTICLE; CLINICAL ASSESSMENT; CORONARY ARTERY BYPASS GRAFT; DELIRIUM; DRUG RESISTANCE; DRUG WITHDRAWAL; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; INTESTINE ISCHEMIA; MAJOR CLINICAL STUDY; MEDIASTINITIS; OFF PUMP CORONARY SURGERY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; STROKE;

ASPIRIN; CORONARY ARTERY BYPASS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; RISK ASSESSMENT;

EID: 68349142980     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02175.x     Document Type: Article

References (23)

1. Collaboration AT. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. Br Med J 2002 324 : 71 86.
2. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 : 234S 64S.
3. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001 88 : 230 5.
4. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002 347 : 1309 17.
5. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001 121 : 982 4.
6. Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 2005 27 : 606 10.
7. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002 13 : 37 40.
8. Weber AA, Przytulski B, Schumacher M, Zimmermann N, Gams E, Hohlfeld T et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002 117 : 424 6.
9. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003 108 : 542 7.
10. Lim E, Carballo S, Cornelissen J, Ali ZA, Grignani R, Bellm S et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl(A2) polymorphism (NCT00262275). Ann Thorac Surg 2007 83 : 134 8.
11. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003 73 : 122 30.
12. Frelinger AL III., Furman MI, Linden MD, Li Y, Fox ML, Barnard MR et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006 113 : 2888 96.
13. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002 107 : 45 9.
14. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract 2006 60 : 863 6.
15. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med 2006 119 : 707e11 6.
16. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006 81 : 104 10. discussion 10-1.
17. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993 71 : 397 403.
18. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997 78 : 1003 7.
19. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 105 : 1650 5.
20. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004 43 : 1122 6.
21. Gurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg 2006 29 : 190 5.
22. Dacey LJ, Munoz JJ, Johnson ER, Leavitt BJ, Maloney CT, Morton JR et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000 70 : 1986 90.
23. Cannon CP, Mehta SR, Aranki SF. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg 2005 80 : 768 79.